Oral Semaglutide (the Wegovy Pill): What the Evidence Actually Shows

On December 22, 2025, FDA approved a new drug application for "Wegovy (semaglutide) tablets" — confirmed directly against the agency's own Drugs@FDA database, which lists the approval under NDA 218316, filed as a "New Dosage Form" submission, with four tablet strengths on file: 1.5 mg, 4 mg, 9 mg and 25 mg¹. Novo Nordisk's own press release, dated January 5, 2026, describes the pill as "now broadly available through 70,000+ US pharmacies such as CVS and Costco," alongside select telehealth providers and its own NovoCare Pharmacy⁹. Both dates check out against primary sources, not secondary coverage repeating each other.

That is genuinely new, and it is easy to get wrong, because "oral semaglutide" already meant something before this approval. Rybelsus — a lower-dose semaglutide tablet — has existed since 2019, for type 2 diabetes only. This is a different product: a higher-dose tablet, approved for weight management, built on a trial program most coverage still calls by the wrong name or the wrong dose. Here is what actually changed, and what didn't.

Three semaglutide products, not two

The confusion starts because "semaglutide" and "Ozempic" and "Wegovy" get used loosely, and now there are three FDA-approved semaglutide products with genuinely different histories, doses and indications:

Rybelsus is the original oral semaglutide, approved under NDA 213051 in September 2019, confirmed live against that application's own Drugs@FDA record². It is labelled only for type 2 diabetes — to improve glycemic control, and separately to reduce cardiovascular risk in adults with type 2 diabetes at high risk for it. Its dosing ladder tops out at 14 mg once daily, and its own current label states plainly that it is "not substitutable on a mg-to-mg basis" with the newer Ozempic-branded tablet that now shares its NDA³. Rybelsus was never approved for weight management in people without diabetes.

Wegovy injection is the once-weekly subcutaneous product approved for chronic weight management starting in 2021, since expanded to cardiovascular risk reduction, a high-dose (7.2 mg) tier, and other indications — covered in detail in our semaglutide dosing chart. Its own pivotal trial, STEP 1, established the approved 2.4 mg dose directly, reporting a mean body-weight change of −14.9% versus −2.4% on placebo at week 68¹¹ — the injection figure this article uses as a baseline throughout. It is the product this site's own compounded-semaglutide coverage exists in reference to, since compounded vials are attempts to replicate this molecule, not the tablet.

Wegovy tablets are the new product this article is about: a 1.5-to-25 mg once-daily oral tablet, approved December 22, 2025 for the same two adult indications the injection already carries — cardiovascular risk reduction in adults with established CV disease and obesity or overweight, and weight reduction with at least one weight-related comorbidity⁶. It is not Rybelsus at a higher dose relabeled; it is a separate approval, on a separate application, with its own trial program.

A fourth entry exists and is worth naming precisely rather than folding into the three above: in 2025, Rybelsus's own NDA (213051) was expanded to add an "Ozempic" tablet, 1.5/4/9 mg — still diabetes-labelled, sharing Rybelsus's current prescribing information and its T2D-only indication³. It is not the weight-management product this article covers, and readers researching "the Wegovy pill" specifically are not looking for it — but a source that flattens "oral semaglutide" to one product now has four to keep straight, not two.

The trial program: OASIS, and the dose that got approved is not the one you'd guess

Wegovy tablets' weight-reduction indication rests on a trial program Novo Nordisk calls OASIS — Oral semaglutide in Adults with overweight or obesity — and the specific dose approved is not the highest one tested.

OASIS 1 (Lancet, 2023) tested oral semaglutide 50 mg once daily against placebo in 667 adults without diabetes over 68 weeks. Its own results: "The estimated mean bodyweight change from baseline to week 68 was −15·1% (SE 0·5) with oral semaglutide 50 mg versus −2·4% (0·5) with placebo (estimated treatment difference −12·7 percentage points, 95% CI −14·2 to −11·3; p<0·0001)⁴." Adverse events were more frequent with the drug (92% vs. 86%), and gastrointestinal events specifically hit 80% of the semaglutide group versus 46% on placebo⁴.

OASIS 4 (NEJM, 2025) is the trial that actually supports what got approved: a 71-week, placebo-controlled trial of oral semaglutide 25 mg — a lower dose than OASIS 1 tested — in 307 adults without diabetes, randomized 2:1. Its own results, quoted directly: "The estimated mean change in body weight from baseline to week 64 was −13.6% in the oral semaglutide group and −2.2% in the placebo group (estimated difference, −11.4 percentage points; 95% confidence interval, −13.9 to −9.0; P<0.001)⁵." Gastrointestinal adverse events were more common with oral semaglutide than placebo, 74.0% versus 42.2%⁵. This is the study the Wegovy tablet label itself reproduces as its own primary efficacy table — the label's own numbers (N=205 tablet / 102 placebo, −13.6% vs. −2.4%, Week 64) match OASIS 4's design and headline figure almost exactly, with the small placebo-arm gap explained by a different missing-data imputation model between the published paper and the label's own analysis⁶.

OASIS 2 (JAMA Internal Medicine, 2025) tested the 50 mg dose specifically in an East Asian population, with and without type 2 diabetes⁷ — a population-specific study, not the pivotal trial for the U.S. approval, mentioned here for completeness rather than as a focus.

Why 25 mg — a dose with a smaller effect size than 50 mg — is the one that got approved is a tolerability tradeoff FDA's own review would have weighed directly: 50 mg produced more weight loss and more gastrointestinal side effects than 25 mg. Neither trial paper states FDA's reasoning explicitly; the pattern in the numbers is what's checkable.

How the pill works: a 1-2% absorption problem, solved by an excipient

The reason there are three separate dosing ladders across these products — 0.25 to 7.2 mg for the injection, 1.5 to 25 mg for the Wegovy tablet, 3 to 14 mg for Rybelsus — is not arbitrary. It is absorption.

Semaglutide is a peptide, and peptides are digested in the gut long before they can reach the bloodstream if swallowed unprotected. The Wegovy tablet label states this directly: "Absolute bioavailability of semaglutide is 89% following subcutaneous administration [but] is estimated to be approximately 1% to 2% following oral tablet administration⁶." That roughly 50-to-90-fold absorption gap is why the oral dose (25 mg) is so much larger in milligrams than the injected one (2.4 mg) for a comparable systemic effect — the tablet is formulated to get a small fraction of a much bigger dose through.

The excipient that makes any of it work is SNAC (salcaprozate sodium), described in the label as co-formulated with semaglutide specifically to facilitate its absorption, which the label states "predominantly occurs in the stomach⁶." That absorption is fragile enough that the label documents a specific, counterintuitive water-volume finding from its own studies: "Semaglutide absorption [area under the curve and peak concentration] was higher following dosing with 50 mL water compared to that of 240 mL water⁶" — which is the reasoning behind the tablet's own instruction to take it with no more than 4 ounces of water, not a larger, more "normal" glass. The full protocol, read off the label: one tablet, on an empty stomach, first thing in the morning, with up to 4 ounces of water and no other liquid, swallowed whole — never split, crushed, chewed or dissolved — followed by at least 30 minutes before eating, drinking anything else, or taking other oral medication⁶. Miss any part of that sequence and the fraction that actually gets absorbed can change; it is not a suggestion attached to an otherwise-forgiving pill.

Injection vs. tablet: what "comparable" actually means here

A natural question is whether the 25 mg tablet and the 2.4 mg injection are simply the same drug in two packages. The label's own language is more precise than that, and worth reading exactly: "In patients with overweight or obesity without type 2 diabetes, semaglutide concentrations following once-daily administration of oral WEGOVY 25 mg tablet are predicted to be comparable to WEGOVY 2.4 mg once-weekly injection, with higher variability in semaglutide concentrations compared to subcutaneous administration⁶." "Predicted" is doing real work in that sentence — this is a modeled comparison, not a head-to-head trial.

That modeling has its own published source. A 2026 paper by Novo Nordisk's own clinical pharmacology team states outright what the label implies: "To fulfil health authority approval requirements, population pharmacokinetic and exposure-response analyses were used to extrapolate efficacy and safety data from subcutaneous to oral semaglutide⁸." Its own reported result: "Most participants (82.2%) treated with oral semaglutide 25 mg in OASIS 4 achieved exposure levels within the same range as participants treated with once-weekly subcutaneous semaglutide 2.4 mg in STEP 1⁸." That 82.2% figure is precise about what it is — a match in drug exposure for most, not all, participants, established by modeling rather than by dosing the same person both ways in one trial.

This modeling distinction has a real regulatory consequence worth stating plainly: the Wegovy tablet's cardiovascular-risk-reduction indication is not backed by its own outcomes trial. Section 14.1 of the current label describes exactly one cardiovascular outcomes trial supporting that indication — "Study 1 (NCT03574597)," a 17,604-patient trial run entirely with WEGOVY injection, in adults with established cardiovascular disease and obesity or overweight, no diabetes⁶. The tablet inherits that indication through the exposure-matching argument above, not through a cardiovascular trial of the tablet itself. That is a legitimate, FDA-accepted regulatory pathway — the same "New Dosage Form" pathway the NDA was filed under — but it is a different kind of evidence than OASIS 1/2/4's direct trials of the tablet for weight, and this article treats the two claims differently for that reason.

One more mix-up worth heading off directly, because the products are easy to conflate: the SOUL trial — a real, separately-run 9,650-patient cardiovascular outcomes trial of oral semaglutide, published in NEJM in 2025 — supports the diabetes-labelled Rybelsus/Ozempic tablet's own CV claim, not the Wegovy tablet's. SOUL enrolled adults with type 2 diabetes and established atherosclerotic disease or chronic kidney disease, using a maximum dose of 14 mg¹⁰ — the Rybelsus/Ozempic-tablet ceiling, not the 25 mg Wegovy-tablet dose, and Rybelsus/Ozempic's own current label indication is explicitly type-2-diabetes-specific³. Citing SOUL for the Wegovy tablet's cardiovascular claim would be citing the right kind of trial for the wrong product.

What this doesn't change about compounded semaglutide

Nothing here bears directly on the legal status of compounded semaglutide, which our dated regulatory timeline already covers, or on what compounded semaglutide actually is, which our companion explainer already covers — including the fact that an FDA-approved oral semaglutide for weight management existed before this specific tablet, once the injection's original label was updated in 2026. What this approval adds to that picture is narrower and more specific: a second, higher-dose, weight-indicated branded tablet now exists alongside the injection, with its own dosing ladder, its own absorption science, and — for the cardiovascular claim specifically — its own evidentiary path rather than a shared one.

It also doesn't change what this site's own reviewed providers sell. This board reviews compounded, injectable semaglutide from telehealth providers — not the FDA-approved branded tablet this article covers. Several reviewed providers do sell a compounded oral semaglutide product (drops or an "ODT" tablet), which is a different, unapproved product built on none of the SNAC absorption engineering described above — a distinction our compounded-semaglutide explainer covers directly. If the injectable, compounded route is what you're actually comparing this against, our semaglutide provider comparison is where this site's own board-reviewed research on that market lives — a bridge to the adjacent product this site reviews, not a claim that any reviewed provider sells the tablet this article is about.

Pricing, briefly

Novo Nordisk's own January 2026 release states out-of-pocket list pricing for the tablet at the starting 1.5 mg dose around $149/month, stepping to $199/month for the 4 mg dose after an introductory period, and up to $299/month at higher doses — with a manufacturer savings offer bringing the cost to as little as $25/month for some insured patients⁹. Those are list and promotional figures from the manufacturer's own release, not a claim about what any individual reader will actually pay; insurance coverage, formulary placement, and eligibility for the savings offer vary and are exactly the kind of thing that changes without this article being updated to match.

The bottom line

FDA approved a new oral semaglutide tablet, branded Wegovy, on December 22, 2025 — confirmed against the agency's own Drugs@FDA record — and Novo Nordisk's own release documents broad U.S. pharmacy availability by January 5, 2026. It is a third semaglutide product distinct from both the injection and from Rybelsus: a 1.5-to-25 mg once-daily tablet, absorbed at roughly 1-2% bioavailability via a SNAC-enabled empty-stomach protocol, tested directly for weight reduction in OASIS 4 (25 mg, the approved dose) and OASIS 1 (50 mg, not approved), and carrying a cardiovascular-risk-reduction indication inherited from the injection's own outcomes trial through pharmacokinetic modeling rather than a tablet-specific trial of its own. None of that changes what this site's own board reviews — compounded, injectable semaglutide remains a separate product from the one described here.